SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 9:30 a.m. US PST on Thursday, January 14, 2016. The conference is being held January 11th through 14th at The Westin St. Francis Hotel in San Francisco, California.
The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com on the day of the presentation. A copy of the presentation materials will also be lodged with the Australian Securities Exchange and filed with the U.S. Securities and Exchange Commission.
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.
United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Communications +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 2 9229 2700 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 Annabel Murphy +61 2 9237 2800


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Instagram Outage Disrupts Thousands of U.S. Users
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 



